BCL2 and lymphoma: Furthermore, DLBCL is an aggressive tumor in itself, and poor clinical outcome is increased by overexpression of MYC and BCL2 proteins (double-expressor lymphoma, DEL) and a post-germinal immunohistochemical subtype of DLBCL (non-germinal center B-cell (non-GCB)-DLBCL) [20].